This study developed bispecific T-cell engager (BiTE)-albumin fusion proteins with tunable FcRn affinity to extend serum half-life and enhance anti-tumor efficacy. Using a double-humanized HSA/hFcRn mouse model, the researchers demonstrated that optimizing albumin-FcRn binding affinity modulates BiTE pharmacokinetics and improves therapeutic outcomes in vivo.
Tuning FcRn binding affinity in BiTE-albumin fusions allows programmable half-life extension, improving therapeutic window and anti-tumor responses.
Humanized double Knockin mouse model expressing human serum albumin (HSA) and human neonatal Fc receptor (hFcRn), developed by genOway (AlbuMus).
Immuno-oncology, Bispecific antibodies, FcRn-targeted therapy, T cell redirection
Humanized Knockin model, HSA Knockin, hFcRn Knockin, Albumin–FcRn interaction studies
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
